CD4+ T Cell Responses in Patients with Chronic Hepatitis C Undergoing Peginterferon/Ribavirin Therapy Correlate with Faster, but Not Sustained, Viral Clearance

Aberle, Judith H.; Perstinger, Gabriela; Weseslindtner, Lukas; Sinzinger, Ursula; Gurguta, Calin; Steindl-Munda, Petra; Kundi, Michael; Popow-Kraupp, Theresia; Ferenci, Peter; Holzmann, Heidemarie
May 2007
Journal of Infectious Diseases;5/1/2007, Vol. 195 Issue 9, p1315
Academic Journal
T cell immune responses may be important for the elimination of chronic hepatitis C virus (HCV) infection during antiviral treatment. In the present study, the kinetics of T cell responses to HCV antigens (NS3-4 and core) were prospectively assessed and were correlated with virologic outcome in 31 patients with chronic HCV infection undergoing peginterferon-α2a/ribavirin therapy. NS3-4—directed T helper cell type 1 (Th1) responses were detected in 77% of patients with a significant decline in viremia at treatment week 4 but were not detected not in those with a slower viral decline. The detectability of NS3-4—directed Th1 responses was associated with faster viremia clearance, was short-lived, and did not seem to be associated with the final treatment outcome.


Related Articles

  • Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin. Delić, Dragan; Nešić, Zorica; Prostran, Milica; Simonović, Jasmina; Švirtlih, Neda // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Nov2005, Vol. 62 Issue 11, p865 

    Background Hepatitis C virus (HCV) infection is the most frequent cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma in the world. Acute hepatitis C is the most commonly asymptomatic liver disease with the development of chronic HCV infection in the majority of infected...

  • Short-Term Treatment and Sustained Virologic Response in Two Chronic Hepatitis C Cases. Erol, Serpil; Parlak, Mehmet // Medical Journal of Trakya University / Trakya Universitesi Tip F;2010, Vol. 27 Issue 1, p92 

    The standard treatment for chronic hepatitis C infection is the combination of pegylated interferon-alpha (Peg-IFN-α) and ribavirin for 48 weeks in patients infected with genotype-1. In genotype-2 or -3 infections, treatment by either conventional IFN-α and ribavirin or Peg-IFN-α with...

  • Study identifies when to re-treat hepatitis C and in which patients. Mayor, Susan // British Journal of Hospital Medicine (17508460);Jun2008, Vol. 69 Issue 6, p319 

    The article reports on the international REPEAT randomized clinical trial involving 942 patients with detectable levels of hepatitis C (HCV) RNA after 12 weeks of treatment with peginterferon alfa-2b and ribavirin. It was observed that patients who show a substantial decrease in HCV RNA have the...

  • PEG-Interferon Alfa-2b for Acute Hepatitis C: A Review. Palumbo, Emilio // Mini Reviews in Medicinal Chemistry;Aug2007, Vol. 7 Issue 8, p839 

    Acute infection due to hepatitis C virus results in a chronic progression in 50-84% of cases. In the light of the risk of developing chronic disease and the response rate to treatment once the disease is established, it is very important to consider early treatment of acute hepatitis C before it...

  • Good Safety Profile and Efficacy of Leucocyte Interferon-α in Combination with Oral Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C. Barbaro, Giuseppe; Grisorio, Benvenuto; Fruttaldo, Luigi; Bacca, Donato; Babudieri, Sergio; Torre, Donato; Francavilla, Ruggiero; Rizzo, Giovanni; Belloni, Giancarlo; Lucchini, Alfio; Annese, Mauro; Matarazzo, Filippo; Hazra, Christina; Barbarini, Giorgio // BioDrugs;2003, Vol. 17 Issue 6, p433 

    Compares the safety profile and efficacy of the antiviral agent ribavirin combined with leucocyte interferon (IFN)-alpha or with recombinant IFNalpha-2b in treatment-naive patients with chronic hepatitis C. Lower number of adverse events in patients receiving leucocyte IFNalpha; Effectiveness...

  • A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. Idrees, Muhammad; Riazuddin, Sheikh // BMC Gastroenterology;2009, Vol. 9, Special section p1 

    Background: The aim of this study was to determine the rate of sustained virological response (SVR) and various factors associated with response rates in chronic hepatitis C infected patients treated with interferon alpha and ribavirin combination therapy. Methods: A retrospective review of...

  • Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Kamal, S. M.; El Tawil, A. A.; Nakano, T.; He, Q.; Rasenack, J.; Hakam, S. A.; Saleh, W. A.; Ismail, A.; Aziz, A. A.; Madwar, M. Ali // Gut;Jun2005, Vol. 54 Issue 6, p858 

    Background: The response rates and duration of peginterferon alpha (PEG-IFN-α) and ribavirin combination therapy in chronic hepatitis C genotype 4, the prevalent genotype in the Middle East and Africa, are poorly documented. Aims: To compare the efficacy and safety of 24, 36, or 48 weeks of...

  • Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin. Yu, Ming-Lung; Liu, Chen-Hua; Huang, Chung-Feng; Tseng, Tai-Chung; Huang, Jee-Fu; Dai, Chia-Yen; Lin, Zu-Yau; Chen, Shinn-Cherng; Wang, Liang-Yen; Hank Juo, Suh-Hang; Chuang, Wan-Long; Kao, Jia-Horng // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: The current stopping rule for peginterferon/ribavirin therapy in hepatitis C virus genotype-1 (HCV-1) patients is based on an early virological response (EVR, defined as >2 log10 viral reduction at treatment week 12). We aimed to explore rapid stopping rules at week 4. Methods: We...

  • Monitoring ribavirin concentration predicts early response, anaemia.  // Reactions Weekly;9/10/2005, Issue 1068, p3 

    Discusses research being done on the importance of ribavirin monitoring concentration in predicting hepatitis C virus (HCV). Reference to a study by A. L. Rendón published in the August 2005 issue of the "Journal of Acquired Immune Deficiency Syndromes"; Mean plasma ribavirin concentrations...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics